Literature DB >> 22477538

von Willebrand factor: at the crossroads of bleeding and thrombosis.

Cécile V Denis1, Peter J Lenting.   

Abstract

Hemostasis and thrombosis represent two sides of the same coin. Hemostasis maintains blood fluidity in the vascular system while allowing for rapid thrombus formation to prevent excessive hemorrhage after blood vessel injury. Thrombosis is a pathologic extension of the normal hemostatic mechanism, occurring when unwanted clot formation develops in certain pathological situations. The molecular mechanisms underlying both phenomena are fundamentally identical. One of the key players in both processes is the plasma glycoprotein von Willebrand factor, which perfectly illustrates this duality between hemostatic and thrombotic mechanisms. The purpose of this review is to discuss novel findings on the role of von Willebrand factor at this interface, and how some of these findings may help develop new therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22477538      PMCID: PMC3677142          DOI: 10.1007/s12185-012-1041-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  77 in total

1.  Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients.

Authors:  Augusto B Federici; Pier M Mannucci; Giancarlo Castaman; Luciano Baronciani; Paolo Bucciarelli; Maria T Canciani; Alessandro Pecci; Peter J Lenting; Philip G De Groot
Journal:  Blood       Date:  2008-09-19       Impact factor: 22.113

2.  Functional impairment of von Willebrand factor in hypertrophic cardiomyopathy: relation to rest and exercise obstruction.

Authors:  Thierry Le Tourneau; Sophie Susen; Claudine Caron; Alain Millaire; Sylvestre Maréchaux; Anne-Sophie Polge; André Vincentelli; Frederic Mouquet; Pierre-Vladimir Ennezat; Nicolas Lamblin; Pascal de Groote; Eric Van Belle; Ghislaine Deklunder; Jenny Goudemand; Christophe Bauters; Brigitte Jude
Journal:  Circulation       Date:  2008-09-22       Impact factor: 29.690

3.  Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD).

Authors:  Sandra L Haberichter; Giancarlo Castaman; Ulrich Budde; Ian Peake; Anne Goodeve; Francesco Rodeghiero; Augusto B Federici; Javier Batlle; Dominique Meyer; Claudine Mazurier; Jenny Goudemand; Jeroen Eikenboom; Reinhard Schneppenheim; Jorgen Ingerslev; Zdena Vorlova; David Habart; Lars Holmberg; Stefan Lethagen; John Pasi; Frank G H Hill; Robert R Montgomery
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

Review 4.  Function of von Willebrand factor in haemostasis and thrombosis.

Authors:  A J Reininger
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

Review 5.  Von Willebrand factor: drug and drug target.

Authors:  Simon F De Meyer; Bauke De Maeyer; Hans Deckmyn; Karen Vanhoorelbeke
Journal:  Cardiovasc Hematol Disord Drug Targets       Date:  2009-03

6.  beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation.

Authors:  Janine J J Hulstein; Peter J Lenting; Bas de Laat; Ron H W M Derksen; Rob Fijnheer; Philip G de Groot
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

Review 7.  Clearance of von Willebrand factor.

Authors:  Cécile V Denis; Olivier D Christophe; Beatrijs D Oortwijn; Peter J Lenting
Journal:  Thromb Haemost       Date:  2008-02       Impact factor: 5.249

8.  Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa.

Authors:  Isabelle Marx; Olivier D Christophe; Peter J Lenting; Alain Rupin; Marie-Odile Vallez; Tony J Verbeuren; Cécile V Denis
Journal:  Blood       Date:  2008-05-16       Impact factor: 22.113

9.  Covalent regulation of ULVWF string formation and elongation on endothelial cells under flow conditions.

Authors:  Y Li; H Choi; Z Zhou; L Nolasco; H J Pownall; J Voorberg; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2008-07-01       Impact factor: 5.824

Review 10.  Platelet adhesion under flow.

Authors:  Zaverio M Ruggeri
Journal:  Microcirculation       Date:  2009-01       Impact factor: 2.628

View more
  18 in total

1.  Guest editorial: Current understanding of thrombosis and hemostasis--from bench to bedside.

Authors:  Toshiyuki Miyata
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

2.  A factor VIII-derived peptide enables von Willebrand factor (VWF)-binding of artificial platelet nanoconstructs without interfering with VWF-adhesion of natural platelets.

Authors:  Hassan Haji-Valizadeh; Christa L Modery-Pawlowski; Anirban Sen Gupta
Journal:  Nanoscale       Date:  2014-05-07       Impact factor: 7.790

3.  A variational Bayes discrete mixture test for rare variant association.

Authors:  Benjamin A Logsdon; James Y Dai; Paul L Auer; Jill M Johnsen; Santhi K Ganesh; Nicholas L Smith; James G Wilson; Russell P Tracy; Leslie A Lange; Shuo Jiao; Stephen S Rich; Guillaume Lettre; Christopher S Carlson; Rebecca D Jackson; Christopher J O'Donnell; Mark M Wurfel; Deborah A Nickerson; Hua Tang; Alexander P Reiner; Charles Kooperberg
Journal:  Genet Epidemiol       Date:  2014-01       Impact factor: 2.135

4.  Functional characterization of tissue factor in von Willebrand factor-dependent thrombus formation under whole blood flow conditions.

Authors:  Yasunori Matsunari; Mitsuhiko Sugimoto; Masaaki Doi; Hideto Matsui; Masahiko Kawaguchi
Journal:  Int J Hematol       Date:  2016-08-25       Impact factor: 2.490

5.  Common and rare von Willebrand factor (VWF) coding variants, VWF levels, and factor VIII levels in African Americans: the NHLBI Exome Sequencing Project.

Authors:  Jill M Johnsen; Paul L Auer; Alanna C Morrison; Shuo Jiao; Peng Wei; Jeffrey Haessler; Keolu Fox; Sean R McGee; Joshua D Smith; Christopher S Carlson; Nicholas Smith; Eric Boerwinkle; Charles Kooperberg; Deborah A Nickerson; Stephen S Rich; David Green; Ulrike Peters; Mary Cushman; Alex P Reiner
Journal:  Blood       Date:  2013-05-20       Impact factor: 22.113

6.  Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis.

Authors:  Natalia I Dmitrieva; Maurice B Burg
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-14       Impact factor: 11.205

Review 7.  von Willebrand factor regulation of blood vessel formation.

Authors:  Anna M Randi; Koval E Smith; Giancarlo Castaman
Journal:  Blood       Date:  2018-06-04       Impact factor: 22.113

8.  Predicting pathological von Willebrand factor unraveling in elongational flow.

Authors:  Sagar Kania; Alparslan Oztekin; Xuanhong Cheng; X Frank Zhang; Edmund Webb
Journal:  Biophys J       Date:  2021-03-16       Impact factor: 4.033

9.  Combined genetic effects of EGLN1 and VWF modulate thrombotic outcome in hypoxia revealed by Ayurgenomics approach.

Authors:  Shilpi Aggarwal; Atish Gheware; Anurag Agrawal; Saurabh Ghosh; Bhavana Prasher; Mitali Mukerji
Journal:  J Transl Med       Date:  2015-06-06       Impact factor: 5.531

10.  Conventional rapid latex agglutination in estimation of von Willebrand factor: method revisited and potential clinical applications.

Authors:  Marianor Mahat; Wan Zaidah Abdullah; Che Maraina Che Hussin
Journal:  J Immunol Res       Date:  2014-12-25       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.